1. Home
  2. GENK vs RNAZ Comparison

GENK vs RNAZ Comparison

Compare GENK & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GEN Restaurant Group Inc.

GENK

GEN Restaurant Group Inc.

HOLD

Current Price

$2.25

Market Cap

9.4M

ML Signal

HOLD

Logo TransCode Therapeutics Inc.

RNAZ

TransCode Therapeutics Inc.

HOLD

Current Price

$7.10

Market Cap

8.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GENK
RNAZ
Founded
2011
2016
Country
United States
United States
Employees
2700
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.4M
8.0M
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
GENK
RNAZ
Price
$2.25
$7.10
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$4.50
N/A
AVG Volume (30 Days)
35.6K
5.4K
Earning Date
05-13-2026
04-15-2026
Dividend Yield
1.88%
N/A
EPS Growth
62.50
N/A
EPS
N/A
N/A
Revenue
$208,380,000.00
N/A
Revenue This Year
$4.79
N/A
Revenue Next Year
$7.48
N/A
P/E Ratio
N/A
N/A
Revenue Growth
15.12
N/A
52 Week Low
$1.43
$6.08
52 Week High
$4.98
$20.99

Technical Indicators

Market Signals
Indicator
GENK
RNAZ
Relative Strength Index (RSI) 70.67 28.10
Support Level $2.20 $6.08
Resistance Level $2.55 $9.37
Average True Range (ATR) 0.17 0.52
MACD 0.09 -0.11
Stochastic Oscillator 69.10 21.32

Price Performance

Historical Comparison
GENK
RNAZ

About GENK GEN Restaurant Group Inc.

GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. The group operates its restaurants in California, Arizona, Hawaii, Nevada, Texas, New York, Oregon, North Carolina, Washington, New Jersey, Florida and South Korea.

About RNAZ TransCode Therapeutics Inc.

TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.

Share on Social Networks: